Please login to the form below
inhaled treatment
This page shows the latest inhaled treatment news and features for those working in and with pharma, biotech and healthcare.
Sanofi and Regeneron share positive data for asthma drug
Over the 52-week trial treatment period, the overall rates of adverse events identified were 61-68%. ... Despite treatment with current standard-of-care inhaled corticosteroids and bronchodilators, those with the condition may continue to experience
Latest news
-
Celltrion submits application for inhaled COVID-19 antibody treatment
A global phase 3 clinical study will evaluate the inhaled antibody cocktail treatment for patients with mild-to-moderate COVID-19 symptoms. ... The benefits of the inhaled treatment means that it can be readily self-administered by patients, using a
-
Oxford study finds standard asthma medication improves recovery time in COVID-19 patients
Early treatment with inhaled budesonide could help high-risk patients. A study led by Oxford University researchers has found the inhaled asthma medication budesonide can shorten recovery time when administered early ... Inhaled budesonide – a type of
-
Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout
We continue to closely monitor treatment with RLT-100T in other hospitals,” he added. ... The FDA has now granted the drug an investigational new drug (IND) authorisation and a fast track designation for intravenous and inhaled delivery for the
-
Vir Biotech plans to start mid-to-late stage study of COVID-19 antibody this month
In May, Vir signed a deal with Biogen to develop and manufacture antibodies for the potential treatment of COVID-19. ... The company also expects to complete preclinical studies of an inhaled SARS-CoV-2 targeting siRNA treatment, VIR-2703, by the end of
-
GSK seeks EU approval for Trelegy in adult asthma patients
The EMA submission is supported by data from the phase 3 CAPTAIN study of Trelegy in adult asthma patients, whose disease remained inadequately controlled despite treatment with a combination of inhaled ... The study met its primary endpoint of
More from news
Approximately 1 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
Deal Watch table for August 2013
Acquisition. Respiratory medicines including the inhaled corticosteroid Aerospan (flunisolide) for the treatment of asthma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
Leading biotechnology company NovaBiotics Ltd have secured a major licensing deal for their fungal nail treatment. ... 1 ready in inhaled form (for the long-term maintenance of respiratory function in CF patients).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
